Sign in
SABS Stock Price, Chart, Stats & News
SAB Biotherapeutics, Inc.
Save
SAB Biotherapeutics, Inc. (SABS) does not currently pay a dividend.
299.35M
Market cap
–
Current P/E
–
Forward P/E
SABS chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | 7.68% |
ROE | 15.17% |
D/E | 0.04x |
Interest coverage ratio | -203.41x |
SABS valuation
P/E | – |
P/S | – |
P/B | 0.49x |
P/CF | -1.66x |
P/FCF | -0.81x |
P/OCF | -1.66x |
PEG | -0.07x |
EV multiple | 2.48x |
About
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Similar securities
Based on sector and market capitalization
Report issue